Page 15 - Celularity Inc News Today

/PRNewswire/ -- Transparency Market Research: Companies in the placental stem cell therapy market have been recently exploring the therapeutic potential of...

The Research & Development Council of New Jersey announced the 2021 Thomas Edison Patent Award winners, along with its special individual

05.08.2021 - Collaboration will initially explore the therapeutic potential of a combination of Imugene’s CF33-CD19 oncolytic virus (onCARlytics) and Celularity’s CD19 targeting chimeric antigen receptor (CAR) placental-derived investigational T-cell therapy, ... Seite 1

Share this article NEW YORK, June 14, 2021 /PRNewswire/ -- The amniotic membrane market is expected to grow by USD 954.86 million during 2021-2025, according to Technavio. The report offers a detailed analysis of the impact of the COVID-19 pandemic on the amniotic membrane market in optimistic, probable, and pessimistic forecast scenarios. Technavio has announced its latest market research report titled Amniotic Membrane Market by Type and Geography - Forecast and Analysis 2021-2025 Technavios...

Share this article Share this article ResearchAndMarkets.coms offering. CAR-T cell therapy is a remarkably promising treatment for cancer patients. It is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as "living drugs." T-cells form the backbone of CAR-T cell therapy. T-cells are the workhorses of our immune sy...

Share this article Share this article FLORHAM PARK, N.J. and GAITHERSBURG, Md., May 25, 2021 /PRNewswire/ -- Celularity, Inc. ("Celularity"), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum human placenta, and MaxCyte, Inc., a leading provider of cell-engineering platform technologies for next generation cell-based therapies, today announce the signing of a strategic...

TRADING UPDATES: Bank of Cyprus outlook hinges on tourism industry Tue, 25th May 2021 19:40 (Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Bank of Cyprus Holdings PLC - Strovolos, Cyprus-headquartered financial services firm - Reports total income of EUR136 million in first quarter of 2020, down from EUR145 million a year prior. Swings to pretax profit of EUR19 million from EUR18 million loss. ...

88 Energy News Headlines. 88E Share News. Financial News Articles for 88 Energy Limited Ord Npv (Di) updated throughout the day.

The Placental Stem Cell Advantage As Celularity makes its most significant clinical progress to date, the company is putting theories born of 20 years of postpartum placental stem cell research into practice. Could the production platform it’s building be the key to accessible, affordable allogeneic cell therapy? Last month, Celularity announced that the FDA granted Orphan Drug Designation status to the company’s lead therapeutic candidate, CYNK-001, for the treatment of malignant gliomas. ...

Share this article Share this article NEW YORK, May 14, 2021 /PRNewswire/ -- GX Acquisition Corp. ("GX") (NASDAQ: GXGX), a publicly-traded special purpose acquisition company, announced today that its stockholders have voted to approve an amendment to GXs amended and restated certificate of incorporation to extend the date by which GX must effectuate its initial business combination  from May 23, 2021 to July 31, 2021. As previously disclosed, on January 8, 2021, GX entered into a Merger Agre...